Concept Map for Diagnosis and Treatment of Congenital Adrenal Hyperplasia (CAH)
The diagnosis and treatment of CAH due to 21-hydroxylase deficiency follows a structured algorithmic approach based on biochemical testing with 17-OHP levels, followed by targeted hormone replacement therapy that prioritizes preventing adrenal crisis while minimizing iatrogenic Cushing's syndrome. 1
DIAGNOSIS PATHWAY
Initial Screening & Clinical Presentation
Step 1: Recognize Clinical Presentations
- Newborns: Ambiguous genitalia in females, salt-wasting crisis (hypovolemia, hyponatremia, hyperkalemia) in both sexes 1
- Children: Accelerated growth, advanced bone age, premature pubic hair 2
- Adolescents/Adults: Severe acne, hirsutism, menstrual irregularity, primary amenorrhea 2
Step 2: Obtain Early Morning Baseline 17-OHP 1
Diagnostic Algorithm Based on 17-OHP Levels
Baseline 17-OHP Interpretation:
| 17-OHP Level | Interpretation | Next Step |
|---|---|---|
| >300 nmol/L (>10,000 ng/dL) | Likely Classic CAH | Proceed to confirmatory testing |
| 6-300 nmol/L (200-10,000 ng/dL) | Likely Nonclassic CAH | ACTH stimulation test required |
| <6 nmol/L (<200 ng/dL) | Likely Unaffected | Consider alternative diagnosis |
ACTH Stimulation Test (for borderline cases):
Perform cosyntropin stimulation with complete adrenocortical profile to differentiate 21-hydroxylase deficiency from other enzyme defects 1
Post-ACTH 17-OHP Interpretation:
| Post-ACTH 17-OHP | Diagnosis |
|---|---|
| >300 nmol/L (>10,000 ng/dL) | Classic CAH |
| 31-300 nmol/L (1,000-10,000 ng/dL) | Likely Nonclassic CAH |
| <50 nmol/L (<1,666 ng/dL) | Unaffected or Heterozygote |
Additional Diagnostic Studies
- Plasma Renin Activity (PRA) & Aldosterone: Elevated PRA with reduced aldosterone/PRA ratio differentiates salt-wasters from simple virilizers 1
- Genotyping: Reserve for equivocal ACTH stimulation test results or genetic counseling purposes only 1
- Other elevated steroids: 21-deoxycortisol, androstenedione, testosterone 1
Critical Pitfall: Genotyping cannot distinguish salt-wasting from simple virilizing forms—this requires clinical evaluation of electrolytes and PRA 1
TREATMENT PATHWAY
Treatment Goals
The fundamental goal is reducing excessive androgen secretion while replacing deficient hormones, balancing between:
- Undertreatment risks: Adrenal crisis, accelerated bone age, loss of growth potential
- Overtreatment risks: Growth suppression, hypertension, iatrogenic Cushing's syndrome 1
GROWING CHILDREN (Pediatric Patients)
Glucocorticoid Therapy
Use hydrocortisone (HC) tablets exclusively in growing patients 1
Dosing:
- 10-15 mg/m²/day divided into 3 daily doses 1
- DO NOT use: Oral HC suspension or chronic long-acting glucocorticoids (prednisone, prednisolone, dexamethasone) in children—these cause growth suppression 1
Rationale: HC's short half-life minimizes adverse effects, particularly growth suppression, compared to longer-acting potent glucocorticoids 1
Initial Management in Infancy:
- May temporarily exceed recommended doses to reduce markedly elevated adrenal hormones
- Rapidly reduce dose once target steroid levels achieved
- Frequent reassessment needed in infancy 1
Critical Pitfall: Attempting to completely normalize 17-OHP levels typically results in overtreatment 1
Mineralocorticoid Therapy
All patients with classic CAH require fludrocortisone and sodium chloride supplements 1
Dosing:
- Fludrocortisone: 0.05-0.2 mg/day divided 1-2 times daily 1
- Sodium chloride: 1-2 g/day (17-34 mEq/day) in infancy, divided in several feedings 1
Monitoring Requirements
Monitor for BOTH:
- Signs of glucocorticoid excess (growth suppression, hypertension, Cushingoid features)
- Signs of inadequate androgen suppression (accelerated bone age, virilization) 1
Assess bone age regularly to detect advanced skeletal maturation 3
FULLY GROWN ADULTS
Transition to longer-acting glucocorticoids is acceptable after growth completion 1
Dosing Options:
| Glucocorticoid | Dose (mg/day) | Daily Frequency |
|---|---|---|
| Hydrocortisone | 15-25 | 2-3 times |
| Prednisone | 5-7.5 | 2 times |
| Prednisolone | 4-6 | 2 times |
| Dexamethasone | 0.25-0.5 | 1 time |
| Fludrocortisone | 0.05-0.2 | 1 time |
STRESS DOSING PROTOCOLS
INCREASE Glucocorticoid Doses For:
- Febrile illness (≥38.5°C)
- Gastroenteritis with dehydration
- Surgery with general anesthesia
- Major trauma 1
DO NOT INCREASE Doses For:
- Mental/emotional stress
- Minor illness
- Physical exercise 1
Provide emergency injectable hydrocortisone for home use in adrenal crisis situations 3
NONCLASSIC CAH MANAGEMENT
Treatment is NOT routinely required unless symptomatic 1
Consider hydrocortisone replacement for:
- Advanced bone age compromising final height
- Significant hyperandrogenic symptoms (severe hirsutism, menstrual irregularity) 3, 2
SURGICAL MANAGEMENT
For severely virilized females:
- Early single-stage genital repair performed by experienced surgeons 1
- Conservative approach increasingly favored: Shift from routine early surgery to individualized decision-making with family involvement 3
SPECIAL CONSIDERATIONS
Newborn Screening
- Universal newborn screening recommended for severe 21-hydroxylase deficiency 1
- Identifies asymptomatic males and prevents salt-wasting crises 3
Prenatal Management
- Prenatal dexamethasone treatment remains experimental 1
- Noninvasive prenatal diagnosis allows targeted treatment, avoiding unnecessary exposure in males and unaffected females 4, 5
Growth-Promoting Therapy
- GnRH analogue therapy may improve final height in select cases with central precocious puberty 3
- Routine use of experimental therapies to promote growth NOT recommended 1
Long-term Monitoring
- Monitor for metabolic syndrome, cardiovascular risks, bone health 6, 7
- Screen for testicular adrenal rest tumors in males 6
- Assess fertility and quality of life 8
EMERGING THERAPIES
Newer approaches under investigation include:
- Modified-release hydrocortisone formulations
- CRF1 receptor antagonists
- Adrenal-targeted drugs
- Experimental gene therapies 6, 7
These remain investigational and are not yet standard of care.